Sovereign Nations. Different Laws. One Complicated Payments System.
Sovereign Nations. Different Laws. One Complicated Payments System. On Indigenous Peoples' Day, it's time to examine why tribal gaming, ...
The dietary supplement industry's approach to antioxidant marketing has undergone fundamental transformation since the USDA discontinued its Oxygen Radical Absorbance Capacity (ORAC) database in 2012, shifting from numerical capacity scores to mechanistic efficacy and clinical validation of biological outcomes.
In the early 2000s, antioxidant capacity dominated supplement marketing through ORAC scores that quantified ingredients' ability to neutralize free radicals in laboratory settings. Ingredient developers promoted increasingly higher values to demonstrate superior oxidative stress protection, positioning açai, blueberries, and cocoa based on their ORAC numbers rather than comprehensive nutritional profiles.
The USDA developed ORAC testing at its Human Nutrition Research Center on Aging in the 1990s, creating what appeared to be a quantifiable standard for antioxidant health benefits from foods. However, the disconnect between in vitro laboratory performance and actual biological effects in humans, combined with widespread marketing misuse, led the USDA to retire the ORAC database in 2012.
"The general opinion among scientists is that in vitro Total Antioxidant Capacity (TAC) assays, like ORAC, have little or no correlation with clinical health status or specific biological functions," stated Jeffrey B. Blumberg, Ph.D., research professor at the Food is Medicine Institute and expert in nutritional antioxidants. "They can't account for how compounds are absorbed, metabolized or distributed in the body. That's why we stopped using them even in pre-screening."
Beyond ORAC, the supplement industry adopted multiple Total Antioxidant Capacity tests including Ferric Reducing Antioxidant Power (FRAP), Total Radical-Trapping Antioxidant Parameter (TRAP), Trolox Equivalent Antioxidant Capacity (TEAC), and 2,2-Diphenyl-1-picrylhydrazyl (DPPH) assays. The multiplication of testing methodologies ultimately undermined their utility rather than strengthening antioxidant science.
"The modest to poor correlation among these assays underscores their limitations," Blumberg explained. "Using them to draw meaningful conclusions for consumers is not scientifically defensible."
The lack of standardization between different TAC assays meant the same ingredient could receive dramatically different scores depending on which test was used, creating confusion rather than clarity for consumers and formulators attempting to compare products or ingredients.
Despite the retirement of ORAC and related capacity metrics, oxidative stress maintains importance in nutrition science, particularly regarding its relationship with inflammation. Current research focuses on the interconnected nature of these biological processes rather than isolated antioxidant capacity measurements.
"We now understand that oxidative stress and inflammation form a vicious cycle," Blumberg noted. "Dietary antioxidants can disrupt this cycle not just by neutralizing radicals, but by activating endogenous defense systems like nuclear factor erythroid 2–related factor 2 (Nrf2), inhibiting pro-inflammatory pathways such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and modulating the gut microbiome."
This mechanistic understanding represents a fundamental shift from measuring antioxidants' ability to neutralize free radicals in test tubes to understanding how dietary compounds interact with cellular signaling pathways, gene expression, and the body's own protective mechanisms.
Lycored, a carotenoid research company, exemplifies the industry's evolution toward mechanistic messaging. The company's Lycomato ingredient—containing lycopene, beta-carotene, phytosterols, phytoene, phytofluene, and tocopherols—positions antioxidants within broader biological outcome frameworks.
"We don't talk about 'antioxidant capacity' anymore," stated Megan Dunn, Lycored's senior manager of global marketing. "We talk about reducing oxidative stress, balancing inflammation and supporting mitochondrial function. For us, it's about systemic resilience, not lab-based performance."
Lycored supports its positioning with over 25 clinical studies demonstrating measurable biological outcomes including increased plasma superoxide dismutase (SOD) activity, reduced inflammatory markers like TNF-α and IL-6, and telomere integrity support—outcomes that address cellular aging and vitality through quantifiable biomarkers rather than capacity scores.
"We're talking about anti-inflammaging and cellular longevity now—concepts that are both scientifically valid and emotionally resonant," Dunn explained. "It's a narrative that bridges regulatory compliance and consumer aspiration."
Artemis International, specializing in berry-derived ingredients, cautioned against ORAC misuse even during the metric's peak popularity. "Even at the height of the antioxidant craze, we were cautioning against misusing ORAC as a definitive health measure," said Melanie Bush, vice president of science and research. "It created a numbers game in the market that quickly became unsustainable."
Artemis now frames antioxidant benefits through health outcome claims supported by human clinical data. "We now speak in terms like 'supports skin health by helping to protect against oxidative stress' rather than 'super antioxidant,'" Bush stated. "The focus is on delivering standardized polyphenols backed by human clinical data."
The company's approach includes demonstrating outcomes such as reduced C-reactive protein (CRP) levels or protection from oxidative stress following exercise. Research also explores bioavailability and gut microbiota interactions, particularly relevant for polyphenols and flavonoids, as mechanisms of action rather than simple antioxidant capacity.
Bush noted that consumer recognition of antioxidants remains strong due to past marketing efforts, particularly from commodity groups like the wild blueberry industry, but messaging has evolved. "Antioxidants are now embedded within broader wellness narratives: cellular health, gut health and inflammation support. They're no longer the headline—they're the mechanism."
The shift toward mechanistic claims reflects stricter scrutiny from regulatory bodies including the U.S. Food and Drug Administration (FDA) and Federal Trade Commission (FTC), which require substantiation beyond in vitro test results. Companies must demonstrate actual biological impact through human clinical studies rather than extrapolating from laboratory antioxidant capacity measurements.
"The movement away from the ORAC ranking system is part of a broader trend toward transparency and scientific rigor," Bush stated. "It's no longer about being the 'highest scoring'—it's about what your ingredient actually does in the body."
This regulatory environment has accelerated industry investment in human clinical trials that measure specific biomarkers, functional outcomes, and health parameters rather than relying on in vitro antioxidant capacity as a proxy for health benefits.
Current antioxidant research emphasizes bioavailability—how compounds are absorbed, metabolized, and distributed in the body—as critical factors that in vitro capacity assays could not address. Many compounds with high ORAC scores demonstrate poor bioavailability, while others with modest capacity scores may be efficiently absorbed and produce significant biological effects.
Metabolic transformations that occur during digestion and first-pass liver metabolism can dramatically alter compounds' chemical structures and biological activities. Understanding these transformations and measuring actual bioactive metabolites in circulation provides more relevant information about potential health effects than measuring parent compounds' antioxidant capacity in test tubes.
Blumberg characterized the evolution as progress beyond simplistic "more is better" thinking. "We're no longer stuck in the paradigm that more is better," he stated. "We're asking better questions—about absorption, pathways and synergy. That's where the future lies."
The synergy concept recognizes that whole foods and complex botanical extracts may produce effects greater than individual isolated compounds, potentially through complementary mechanisms that in vitro single-compound testing cannot capture. This understanding supports whole-food-based supplement formulations and complex botanical extracts over isolated antioxidant compounds.
The transformation from ORAC-based marketing to mechanistic claims requires consumer education about what antioxidant supplements actually do in the body. Rather than competing on numerical scores, brands must communicate biological mechanisms and clinical outcomes in accessible language that maintains scientific accuracy.
Dunn observed strong market receptivity to this approach: "We've seen a real hunger from brands and consumers alike for substantiated, holistic benefits. Not just antioxidants, but what they enable—resilience, longevity and quality of life."
This consumer sophistication reflects broader wellness industry trends toward personalization, evidence-based products, and understanding how supplements support specific biological functions rather than accepting vague "antioxidant" claims as sufficient justification for purchase.
As the industry moves beyond capacity scores, clinical validation becomes a primary competitive differentiator. Companies investing in human clinical trials demonstrating specific health outcomes gain market advantages over competitors making unsupported antioxidant claims based on in vitro testing.
The cost and time required for clinical validation create barriers to entry that may consolidate the antioxidant ingredient market among established players with resources to conduct rigorous research. However, this consolidation may benefit consumers by improving overall claim substantiation and reducing misleading marketing.
As the supplement industry shifts toward mechanistic efficacy and clinical validation, manufacturers need robust quality management systems to document research, maintain regulatory compliance, and substantiate health claims. Qredible's Q-Trust quality management platform provides clinical study documentation, claim substantiation tracking, regulatory compliance monitoring, and quality control systems specifically designed for dietary supplement and nutraceutical companies. Contact our team to learn how our compliance solutions can help your business navigate evolving claim substantiation requirements, maintain documentation for regulatory audits, and position products with scientifically validated mechanistic messaging that meets FDA and FTC standards.
